We will present the case of a patient with nonischemic cardiomyopathy who underwent heart transplantation from a genetically modified pig source animal and whose course was notable for detection of porcine CMV by plasma microbial cell-free DNA and xenograft failure.
1. Describe infectious disease risk assessment and mitigation in potential xenograft donors
2. Describe the selection of immunosuppressive regimens and prophylactic antimicrobials for human xenograft recipients
3. Understand strategies to screen for and treat potential xenograft-related infections